Drugs / Trabectidin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03164980 | Feb 2018 → Aug 2023 | ovarian carcinoma | North Eastern German Society of Gynaecological Oncology | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-09-08 | PharmaMar | Results PharmaMar announces the data to be presented at ESMO 2022 pharmamar.com ↗
PharmaMar (MSE:PHM) announces that new data on Zepzelca® (lurbinectedin) and Yondelis® (trabectedin) will be presented at the European Society for Medical Oncology (ESMO) congress, which is being held in Paris from 9th to 13th September. |
| 2021-09-20 | PharmaMar | Results New results with Yondelis® (trabectedin) in sarcoma will be presented at ESMO 2021 pharmamar.com ↗
The study achieved its primary endpoint of Progression Free Survival. |
| 2021-04-23 | PharmaMar | Regulatory The Australian TGA approves Yondelis® (trabectedin) for Soft Tissue Sarcoma (Liposarcoma or Leiomyosarcoma) pharmamar.com ↗
PharmaMar (MSE:PHM) has announced today that its licensing partner, Specialised Therapeutics Asia, Pte. Ltd. (STA) has received marketing approval for Yondelis® (trabectedin) by the Australian Therapeutic Goods Administration (TGA) for the treatment of patients with unresectable or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS), who have received a prior anthracycline-containing regimen. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-06 | PharmaMar | PharmaMar receives a US$10 million milestone payment from Janssen for Yondelis® pharmamar.com ↗ |
| 2024-11-05 | PharmaMar | PharmaMar receives US$10 million milestone payment from Janssen for Yondelis® pharmamar.com ↗ |
| 2022-09-08 | PharmaMar | PharmaMar announces the data to be presented at ESMO 2022 pharmamar.com ↗ |
| 2021-09-20 | PharmaMar | New results with Yondelis® (trabectedin) in sarcoma will be presented at ESMO 2021 pharmamar.com ↗ |
| 2021-04-23 | PharmaMar | The Australian TGA approves Yondelis® (trabectedin) for Soft Tissue Sarcoma (Liposarcoma or Leiomyosarcoma) pharmamar.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trabectidin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03164980 ↗ |
| Known as | Yondelis | “Trabectidin (Yondelis)” NCT03164980 ↗ |